Pfizer's Xeljanz matches immunosuppressant combo in rheumatoid arthritis study
admin 13th June 2019 Uncategorised 0Pfizer’s troubled JAK inhibitor Xeljanz has had its share of hiccups after pulmonary embolism fears derailed the drug’s higher dose in rheumatoid arthritis. Now, Pfizer is hoping for better results using Xeljanz to treat RA patients who wean off immunosuppressants.
More: Pfizer's Xeljanz matches immunosuppressant combo in rheumatoid arthritis study
Source: fierce